PMC8295557_01
Clinical course of Patient 1# (A) and Patient 2# (B). ETV, Entecavir; TDF, Tenofovir disoproxil fumarate; TAF, Tenofovir alafenamide.
fmed-08-701061-g0001.jpg
PMC8295557_02_fmed-08-701061-g0001.jpg
F1
HIV and HCV antibody was negative for this patient. He started ETV monotherapy (0.5 mg/day) at that time (Figure 1B). TAF (25 mg/day) and ETV (0.5 mg/day) in November 2020. The clinical course of this patient is shown in Figure 1B.
PMC8295557_02
Clinical course of Patient 1# (A) and Patient 2# (B). ETV, Entecavir; TDF, Tenofovir disoproxil fumarate; TAF, Tenofovir alafenamide.
fmed-08-701061-g0001.jpg
PMC8295557_02_fmed-08-701061-g0001.jpg
F1
HIV and HCV antibody was negative for this patient. He started ETV monotherapy (0.5 mg/day) at that time (Figure 1B). TAF (25 mg/day) and ETV (0.5 mg/day) in November 2020. The clinical course of this patient is shown in Figure 1B.